Evaluation of IL-29 in Euthyroid Patients with Graves’ Orbitopathy: A Preliminary Study

Table 2

Clinical and biochemical characteristics of the study participants with Grave’s disease with Graves’ orbitopathy—GD with GO vs. participants with Graves’ disease without GO—GD without GO.

Parameter	Values		value
	GD with GO ()	GD without GO ()
Age (years)	53 (46-59)	46 (35-51)	0.006
Male sex, (%)	9 (29)	5 (29)	0.761^1
WBC, 1000/μL	6.59 (5.89-7.52)	7.34 (6.22-8.37)	0.253
hsCRP (mg/L)	1.5 (0-3.8)	1.0 (0.4-1.6)	0.281
ALT (U/L)	20 (13-26)	17 (15-25)	0.796
AST (U/L)	19 (16-26)	18 (16-22)	0.813
TPOAb (U/mL)	174 (58-259)	56 (27-114)	0.033
TGAb (U/mL)	133 (27-267)	32 (10-251)	0.203
TRAb (U/L)	13.56 (4.29-27.8)	1.79 (0.89-2.92)	<0.001
TSH (μIU/mL)	1.38 (0.65-2.08)	1.45 (0.68-2.06)	0.872
FT3 (pmol/L)	4.3 (3.9-5.23)	4.67 (4.46-5.2)	0.025
FT4 (pmol/L)	17.8 (13.6-19.31)	15.81 (14.43-16.02)	0.126
IL-29 (pg/mL)	165 (133-747)	62 (62-558)	0.031

Data are presented in the form of number (%) or median (IQR).
The italic values are those which are statistically significant.
¹Chi-squared test with Yates’s correction; Mann–Whitney test in other cases, where it is not marked with the superscript one.
ALT: alanine transaminase; AST: aspartate transaminase; FT3: free triiodothyronine; FT4: free thyroxine; hsCRP: high-sensitivity C-reactive protein; IQR: interquartile range; TGAb: antithyroglobulin antibodies; TPOAb: antithyroid peroxidase antibodies; TRAb: anti-TSH receptor antibodies; TSH: thyroid-stimulating hormone; U: unit; WBC: white blood cells.